AstraZeneca has reported positive results from a crucial Phase III trial that demonstrates that patients with a common kind of advanced lung cancer live much longer when using its top cancer treatment, Tagrisso (osimertinib), in conjunction with chemotherapy. A new standard for treating EGFR-mutated non-small cell lung cancer (NSCLC) has been established by the results of the FLAURA2 study.
When combined with chemotherapy, Tagrisso improved overall survival in a statistically significant and clinically meaningful way compared to using Tagrisso alone, which is the current standard of treatment, according to the FLAURA2 Phase III trial’s final overall survival analysis. Patients with locally progressed or metastatic EGFR-mutated non-small cell lung cancer are treated with this combo treatment.
Read More: AstraZeneca’s Datroway Receives US Approval for EGFR-Mutated Lung Cancer
It was determined that the safety profile of the combination of Tagrisso with chemotherapy was controllable and in line with the known profiles of the separate medications. Although there was a larger frequency of adverse events with the addition of chemotherapy, these were mostly predicted, and both study arms had low treatment discontinuation rates.
When treating lung cancer, the aim is to both prolong survival and improve the patient experience, especially in 1st-line where treatment duration can be long and many patients remain active. These positive results support osimertinib, either as monotherapy or in combination with chemotherapy, as standard of care for patients with 1st-line advanced EGFR-mutated lung cancer and reinforce the meaningful benefit of the combination in the current clinical setting. The observed survival benefit is particularly impressive given that FLAURA2 did not impose any restrictions on the choice of subsequent treatment after disease progression.
Pasi A. Jänne
According to AstraZeneca Executive Vice President, Oncology R&D Susan Galbraith, the FLAURA2 results support Tagrisso as the main treatment for EGFR-mutated lung cancer. The information offers strong proof of the combo therapy’s advantages and validates its initial promise.
In a number of nations, including the US, EU, China, and Japan, the combination of Tagrisso and chemotherapy has already been approved by regulators for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer. The complete, comprehensive findings from the FLAURA2 trial’s final overall survival analysis will be shared with international regulatory bodies and presented at a future medical conference. It is anticipated that this new information would strengthen the position of combination therapy in the field of treatment for this
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
